Date: 2013-06-24
Type of information: Licensing agreement
Compound: VM101 (antibody against an undisclosed hematological cancer target)
Company: VivaMab (USA - China) ADC Therapeutics (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: undisclosed hematological cancer
Details: * On June 24, 2013, VivaMab, a therapeutic development division of BioAtla (protein therapeutics service provider with facilities in San Diego and Beijing), and ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (\'ADCs\'), have announced a licensing deal for a novel antibody against an undisclosed hematological cancer target. Under the terms of the deal, ADC Therapeutics has licensed a VivaMab antibody (VM101) produced using BioAtla’s Express Humanization™, Comprehensive Positional Evolution™, Combinatorial Protein Synthesis™ affinity and functional maturation technology platforms. VM101 has been combined with a third-generation cytotoxic pyrrolobenzodiazepine (PBD)-based warhead and proprietary linker technology to form a novel ADC, which has already been shown to have powerful in vivo efficacy in established models for normally intractable hematological cancer indications.
ADC Therapeutics plans to initiate pre-IND development of this proprietary ADC immediately, in parallel with its other advanced ADC programs.
Financial terms: VivaMab will provide development support and will receive a share of potential milestones and royalties on the drug. Financial terms were not disclosed and remain confidential.
Latest news:
